Gabriel Bandeira1, Katia Rocha1, Monize Lazar1, Suzana Ezquina1, Guilherme Yamamoto1,2, Monica Varela1, Vanessa Takahashi1, Meire Aguena1, Thomaz Gollop3, Mayana Zatz1, Maria Rita Passos-Bueno1, Ana Krepischi1, Oswaldo Keith Okamoto4. 1. Departamento de Genética e Biologia Evolutiva, Instituto de Biociências, Centro de Pesquisa Sobre o Genoma Humano e Células-Tronco, Universidade de São Paulo, Cidade Universitária, Rua do Matão 277, São Paulo, SP, CEP: 05508-090, Brazil. 2. Genetics Unit, Faculty of Medicine, Children's Institute, Clinics Hospital, University of Sao Paulo, São Paulo, Brazil. 3. Department of Gynecology and Obstetrics, Faculty of Medicine of Jundiai, São Paulo, Brazil. 4. Departamento de Genética e Biologia Evolutiva, Instituto de Biociências, Centro de Pesquisa Sobre o Genoma Humano e Células-Tronco, Universidade de São Paulo, Cidade Universitária, Rua do Matão 277, São Paulo, SP, CEP: 05508-090, Brazil. keith.okamoto@usp.br.
Abstract
BACKGROUND: It is estimated that 5-10% of breast cancer cases are hereditary. The identification of pathogenic germline variants allows individualized preventive health care, improvement of clinical management and genetic counseling. Studies in ethnically admixed Latin American populations have identified regions with increased frequency of deleterious variants in breast cancer predisposing genes. In this context, the Brazilian population exhibits great genetic heterogeneity, and is not well represented in international databases, which makes it difficult to interpret the clinical relevance of germline variants. METHODS: We evaluated the frequency of pathogenic/likely pathogenic (P/LP) germline variants in up to 37 breast cancer predisposing genes, in a cohort of 105 breast and/or ovarian cancer Brazilian women referred to two research centers between 2014 and 2019. RESULTS: A total of 22 patients (21%) were found to carry P/LP variants, and 16 VUS were detected in 15 patients (14.3%). Additionally, a novel pathogenic ATM intragenic deletion was identified in an early-onset breast cancer. We also detected a BRCA1 pathogenic variant (c.5074+2T>C) in higher frequency (10×) than in other studies with similar cohorts. CONCLUSIONS: Our findings contribute to the characterization of the genetic background of breast cancer predisposition in the Brazilian population as a useful resource to discriminate between deleterious variants and VUS, thus enabling improvement in the preventive health care and clinical management of carriers.
BACKGROUND: It is estimated that 5-10% of breast cancer cases are hereditary. The identification of pathogenic germline variants allows individualized preventive health care, improvement of clinical management and genetic counseling. Studies in ethnically admixed Latin American populations have identified regions with increased frequency of deleterious variants in breast cancer predisposing genes. In this context, the Brazilian population exhibits great genetic heterogeneity, and is not well represented in international databases, which makes it difficult to interpret the clinical relevance of germline variants. METHODS: We evaluated the frequency of pathogenic/likely pathogenic (P/LP) germline variants in up to 37 breast cancer predisposing genes, in a cohort of 105 breast and/or ovarian cancer Brazilian women referred to two research centers between 2014 and 2019. RESULTS: A total of 22 patients (21%) were found to carry P/LP variants, and 16 VUS were detected in 15 patients (14.3%). Additionally, a novel pathogenic ATM intragenic deletion was identified in an early-onset breast cancer. We also detected a BRCA1 pathogenic variant (c.5074+2T>C) in higher frequency (10×) than in other studies with similar cohorts. CONCLUSIONS: Our findings contribute to the characterization of the genetic background of breast cancer predisposition in the Brazilian population as a useful resource to discriminate between deleterious variants and VUS, thus enabling improvement in the preventive health care and clinical management of carriers.
Entities:
Keywords:
ATM; BRCA1; BRCA2; Breast and ovarian cancer susceptibility; Hereditary breast and ovarian cancer (HBOC)
Authors: Ana Rafaela de Souza Timoteo; Ana Élida Menezes Magalhães Gonçalves; Lucas Amadeus Porpino Sales; Betina Menezes Albuquerque; Jorge Estefano Santana de Souza; Patrícia Cristina Pascoto de Moura; Marcos Alberto Arruda de Aquino; Lucymara Fassarela Agnez-Lima; Tirzah Braz Petta Lajus Journal: Breast Cancer Res Treat Date: 2018-08-29 Impact factor: 4.872
Authors: Laureen Ribassin-Majed; Sophie Marguet; Anne W M Lee; Wai Tong Ng; Jun Ma; Anthony T C Chan; Pei-Yu Huang; Guopei Zhu; Daniel T T Chua; Yong Chen; Hai-Qiang Mai; Dora L W Kwong; Shie-Lee Cheah; James Moon; Yuk Tung; Kwan-Hwa Chi; George Fountzilas; Jean Bourhis; Jean Pierre Pignon; Pierre Blanchard Journal: J Clin Oncol Date: 2016-12-05 Impact factor: 44.544
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Gabriela C Fernandes; Rodrigo A D Michelli; Henrique C R Galvão; André E Paula; Rui Pereira; Carlos E Andrade; Paula S Felicio; Cristiano P Souza; Deise R P Mendes; Sahlua Volc; Gustavo N Berardinelli; Rebeca S Grasel; Cristina S Sabato; Danilo V Viana; Edmundo C Mauad; Cristovam Scapulatempo-Neto; Banu Arun; Rui M Reis; Edenir I Palmero Journal: Oncotarget Date: 2016-12-06
Authors: Felipe C Silva; Bianca Cg Lisboa; Marcia Cp Figueiredo; Giovana T Torrezan; Erika Mm Santos; Ana C Krepischi; Benedito M Rossi; Maria I Achatz; Dirce M Carraro Journal: BMC Med Genet Date: 2014-05-15 Impact factor: 2.103
Authors: Edenir Inêz Palmero; Dirce Maria Carraro; Barbara Alemar; Miguel Angelo Martins Moreira; Ândrea Ribeiro-Dos-Santos; Kiyoko Abe-Sandes; Henrique Campos Reis Galvão; Rui Manuel Reis; Cristiano de Pádua Souza; Natalia Campacci; Maria Isabel Achatz; Rafael Canfield Brianese; Maria Nirvana da Cruz Formiga; Fabiana Baroni Makdissi; Fernando Regla Vargas; Anna Cláudia Evangelista Dos Santos; Hector N Seuanez; Kelly Rose Lobo de Souza; Cristina B O Netto; Patrícia Santos-Silva; Gustavo Stumpf da Silva; Rommel M R Burbano; Sidney Santos; Paulo Pimentel Assumpção; Izabel Maria Monteiro Bernardes; Taisa Manuela Bonfim Machado-Lopes; Thais Ferreira Bomfim; Maria Betânia Pereira Toralles; Ivana Nascimento; Bernardo Garicochea; Sergio D Simon; Simone Noronha; Fernanda Teresa de Lima; Anisse Marques Chami; Camila Matzenbacher Bittar; Jose Bines; Osvaldo Artigalas; Maria Del Pilar Esteves-Diz; Tirzah Braz Petta Lajus; Ana Carolina Leite Vieira Costa Gifoni; Rodrigo S C Guindalini; Terezinha Sarquis Cintra; Ida V D Schwartz; Pricila Bernardi; Diego Miguel; Sonia Tereza Dos Santos Nogueira; Josef Herzog; Jeffrey N Weitzel; Patricia Ashton-Prolla Journal: Sci Rep Date: 2018-06-15 Impact factor: 4.379
Authors: George W Sledge; Masakazu Toi; Patrick Neven; Joohyuk Sohn; Kenichi Inoue; Xavier Pivot; Olga Burdaeva; Meena Okera; Norikazu Masuda; Peter A Kaufman; Han Koh; Eva-Maria Grischke; PierFranco Conte; Yi Lu; Susana Barriga; Karla Hurt; Martin Frenzel; Stephen Johnston; Antonio Llombart-Cussac Journal: JAMA Oncol Date: 2020-01-01 Impact factor: 31.777